These authors contributed equally to this work.
Ubiquitylation in immune disorders and cancer: from molecular mechanisms to therapeutic implications
Article first published online: 25 JUN 2012
Copyright © 2012 EMBO Molecular Medicine
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
EMBO Molecular Medicine
Volume 4, Issue 7, pages 545–556, July 2012
How to Cite
Fulda, S., Rajalingam, K. and Dikic, I. (2012), Ubiquitylation in immune disorders and cancer: from molecular mechanisms to therapeutic implications. EMBO Mol Med, 4: 545–556. doi: 10.1002/emmm.201100707
- Issue published online: 3 JUL 2012
- Article first published online: 25 JUN 2012
- Manuscript Accepted: 11 MAY 2012
- Manuscript Revised: 30 APR 2012
- Manuscript Received: 18 JAN 2012
- Funded Access
- cell death;
Conjugation of ubiquitin to proteins (ubiquitylation) has emerged to be one of the most crucial post-translational modifications controlling virtually all cellular processes. What was once regarded as a mere signal for protein degradation has turned out to be a major regulator of molecular signalling networks. Deregulation of ubiquitin signalling is closely associated with various human pathologies. Here, we summarize the current knowledge of ubiquitin signalling in immune deficiencies and cancer as well as the available therapeutic strategies targeting the ubiquitin system in combating these pathogenic conditions.